An interventional study of Step count increase with the use of a motivational smartphone application in Movement Disorders and Parkinson Disease, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-20.
Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.
Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2021, is one of 15 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 17th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:
Radboud University Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in United States, Netherlands
Ages 50+
Radboud University Medical Center · Sites in Netherlands
Ages 50+
Radboud University Medical Center · Sites in Netherlands
Ages 18+ · Healthy volunteers
Radboud University Medical Center
Ages 30–75
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 452 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 188 across the 22 interventional studies, 133 across the 12 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Parkinson Disease by Radboud University Medical Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07316296Phase 3Radboud University Medical CenterPharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach | 2027-07-01 |
| NCT06669455Radboud University Medical CenterAn Integrated and Personalized Lifestyle Approach for People With Parkinson's Disease | 2027-03 |
| NCT06573866Radboud University Medical CenterEnhancement of Quality of Work And Life | 2027-03-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Parkinson Disease by Radboud University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).
Rationale: Exercise affords health benefits for people with Parkinson's disease (PD), but implementing exercise in daily life remains challenging. Moreover, many training programs are not very scalable. The investigators take an important step forward by developing and studying an innovative and fully decentralized smartphone-based program to increase long-term physical activity in people with PD in daily life.
Objective: The aim of this study is to investigate whether a smartphone app can increase physical activity in PD patients for a long period of time (12 months). The secondary aim is to test the potential group effect on physical fitness, motor- and non-motor symptoms. Thirdly, we aim to investigate whether there is a dose-response relationship between amount of physical activity and physical fitness, motor- and non-motor functioning.
Study design: Double-blind randomized controlled trial.
Study population: A total of 452 Dutch patients with PD who have no other medical conditions that markedly hamper mobility other than PD, no cognitive impairments that make it difficult to use a game on the smartphone and possess a suitable smartphone, will be recruited.
Intervention: Participants will be randomized to a group that will be motivated to increase their physical activity level to a small, medium, large or very large degree with respect to their own baseline level.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 452 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Parkinson Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Movement Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Very large proportional increase in stepcount relative to baseline stepcount.
Behavioral: Step count increase with the use of a motivational smartphone application
Large proportional increase in stepcount relative to baseline stepcount.
Behavioral: Step count increase with the use of a motivational smartphone application
Medium proportional increase in stepcount relative to baseline stepcount.
Behavioral: Step count increase with the use of a motivational smartphone application
Small proportional increase in stepcount relative to baseline stepcount.
Behavioral: Step count increase with the use of a motivational smartphone application
All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
Mean change in step count per day
Mean change in step count per day as measured continuously with the participant's smartphone from baseline (week -4 to 0) to follow-up (week 49-52). Higher scores indicate more physical activity (steps).
Time frame: Week -4 until 0 and week 49 until 52
Change in physical fitness (6MWT)
Change from baseline in meters walked during the six minute walk test (6MWT) at week 53 (follow-up). Higher scores indicate better function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in motor- and non-motor aspects of daily living
Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) parts Ib and II at 53 weeks (follow-up). Range 0-80. Higher scores indicate worse function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in physical fitness (VO2max)
Change from baseline in VO2max in ml/kg/min assessed by a maximal aerobic exercise test on a cycle ergometer at follow-up (week 53). Higher scores indicate better function. Performed in a subgroup of 100 participants.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in Parkinson's Disease symptoms (MDS-UPDRS)
Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) at 53 weeks (follow-up). Range 0-199. Higher scores indicate worse function. Total scores for Parts I, II, III, and IV will also be calculated.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in ambulatory capacity (MDS-UPDRS)
Change from baseline in the sum of 5 MDS-UPDRS questions: walking and balance \[question 2.12\], freezing \[q. 2.13\], gait \[q. 3.10\], freezing of gait \[q. 3.11\], and postural stability \[q. 3.12\]). Higher scores imply worse symptoms.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in mobility (TUG)
Change from baseline in the time (seconds) needed to complete the Timed Up and Go Test (TUG) at 53 weeks (follow-up). Higher scores indicate worse function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in balance (Mini-BestTest)
Change from baseline on the Mini-BestTest at 53 weeks (follow-up).Range 0-28. Higher scores indicate better function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in gait speed (10MWT)
Change from baseline in gait speed (m/s) as assessed by the 10 meter walk test (10MWT). Higher scores indicate better function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in fear of falling (FES-I)
Change from baseline on the Dutch version of the Falls Efficacy Scale International at 53 weeks (follow-up). Range 16-64. Higher scores indicate higher fear of falling.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Number of falls and near-falls (monthly fall diary)
Number of falls and near-falls reported monthly by the participants in a fall diary drafted according to the European Physiotherapy guideline for Parkinson's Disease.
Time frame: Every four weeks after start of the intervention (at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 weeks).
Change in handgrip strength
Change from baseline in hand grip strength (kg) as assessed with a dynamometer (best out of three attempts).
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in self-reported physical activity level (LAPAQ)
Change from baseline on the Longitudinal Aging Study Amsterdam (LASA) physical Activity Questionnaire (LAPAQ). Higher scores indicate a higher physical activity level.
Time frame: Week -4 (screening), week 0 (baseline) and week 53 (follow-up)
Change in cognition (MOCA)
Change from baseline on the Montreal Cognitive Assessement (MOCA) score at 53 weeks (follow-up). Range 0-30. Higher scores indicate better cognition.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in depression and anxiety (HADS)
Change from baseline on the Hospital Anxiety and Depression Scale (HADS) at 53 weeks (follow-up). Range 0-42. Higher scores indicate worse function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in apathy (AES-12PD)
Change from baseline on the Apathy Evaluation Scale (AES-12PD) at 53 weeks (follow-up). Range 12-48. Higher scores indicate better function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in fatigue (FSS)
Change from baseline on the Fatigue Severity Scale (FSS) at 53 weeks (follow-up). Range 1-7. Higher scores indicate worse function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in severity of sleep problems and daytime sleepiness (SCOPA-SLEEP)
Change from baseline on the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep) questionnaire at 53 weeks (follow-up).
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in autonomic dysfunction (SCOPA-AUT)
Change from baseline on the Scales for Outcomes in Parkinson's Disease - autonomic questionnaire (SCOPA-AUT) at 53 weeks (follow-up).
Time frame: Week 0 (baseline) and week 53 (follow-up)
Change in Health related quality of life (PDQ-39)
Change from baseline on the Health related quality of life (PDQ-39) questionnaire at 53 weeks (follow-up). Range 0-100. Higher scores indicate better function.
Time frame: Week 0 (baseline) and week 53 (follow-up)
Perceived effect of intervention (GPE)
Perceived effect of intervention as assessed by the Global Perceived effect (GPE) questionnaire (7-point scale) at 53 weeks (follow-up). Range 1-7. Higher scores indicate higher perceived effect.
Time frame: At week 53 (follow-up)
System Usability (SUS)
Usability of the STEPWISE application as assessed by the Dutch version of the System Usability Scale (SUS) at 53 weeks (follow-up). Range 0-100. Higher scores indicate better usability.
Time frame: At week 53 (follow-up)
Perceived physical ability (LIVAS)
Change from baseline on the percieved physical ability scale (Lichamelijke Vaardigheden Schaal; LIVAS) at 53 weeks (follow-up). Range 10-50. Higher scores indicate higher perceived phisical ability.
Time frame: Week 0 (baseline) and week 53 (follow-up)
STEPWISE Parkinson smartphone application data
User data from the STEPWISE smartphone application will be collected, including number of interactions with the app and the total time the application was used.
Time frame: From baseline (week 0) to follow-up (week 53)
Adherence to the intervention
Adherence to the study intervention as indicated by the number of days the STEPWISE app was used.
Time frame: From baseline (week 0) to follow-up (week 53)
Barriers and motivators to engage in exercise/physical activity at baseline and follow-up
Barriers and motivators to engage in exercise/physical activity reported on the self-developed Barriers and Motivators questionnaire at week 0 (baseline) and week 53 (follow-up).
Time frame: Week 0 (baseline) and week 53 (follow-up)
Exploratory measurement of physical acitivity with wearable sensor
Movement data captured with a 6-axis inertial movement sensor (Axivity AX6).
Time frame: From week 0 (baseline) to week 1 and from week 52 to week 53 (follow-up)
Parkinson's disease symptoms monitored with the mPower app
Parkinson's disease symptoms monitored remotely with the mPower smartphone app.
Time frame: Every three months from week 0 (baseline) to week 53 (follow-up)
Blood-based biomarkers
Change in blood-based biomarkers. Assays will be determined before unblinding. Collected for a subgroup of participants (maximum n=135).
Time frame: Week 0 (baseline) and week 53 (follow-up)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will make relevant and anonymised data available in a validated database.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication of the main results of our trial.
Access criteria: Access to the data is restricted, meaning that researchers who are interested in re-use of the data are asked to contact the central contact person for permission. Approval is given after a signed agreement.
Started May 2021 (actual). Primary completion is estimated for Sep 2026, 64 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 64 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center →